Quick answers
- What is Elafibranor used for?
- The FDA-approved label (Iqirvo, Ipsen Biopharmaceuticals, Inc., August 11, 2026) says: “IQIRVO is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. This indication is approved under accelerated approval based on reduction of alkaline phosphatase (ALP) […]. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Elafibranor have a boxed warning?
- No. None of the 1 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Elafibranor?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Elafibranor been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Elafibranor?
- 1 company lists prescription products of Elafibranor in the FDA NDC Directory, including Ipsen Biopharmaceuticals, Inc..
What Elafibranor is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
IQIRVO is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. This indication is approved under accelerated approval based on reduction of alkaline phosphatase (ALP) […]. …
— FDA label: Iqirvo, Ipsen Biopharmaceuticals, Inc., effective August 11, 2026. Read the full label on DailyMed →
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
Forms and how it is given
| Dosage forms | Tablet, film coated |
|---|---|
| Route | Oral |
| Prescription products | 1 in the FDA NDC Directory |
| Brand names | Iqirvo |
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Ipsen Biopharmaceuticals, Inc.1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA218860 IQIRVO | Ipsen | June 10, 2024 | 1, latest August 7, 2026 2026: Labeling |
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 2684946, 2684952 |
|---|---|
| SPL set ID of the quoted label | d78aa14f-6ec1-4b1d-a4ae-e48658137a25 |
| FDA labels (SPL) | 1 |
| FDA applications | NDA218860 |
| Active ingredients (FDA) | ELAFIBRANOR |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Iqirvo, Ipsen Biopharmaceuticals, Inc., effective August 11, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →